AR106351A1 - Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento - Google Patents

Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento

Info

Publication number
AR106351A1
AR106351A1 ARP160103143A ARP160103143A AR106351A1 AR 106351 A1 AR106351 A1 AR 106351A1 AR P160103143 A ARP160103143 A AR P160103143A AR P160103143 A ARP160103143 A AR P160103143A AR 106351 A1 AR106351 A1 AR 106351A1
Authority
AR
Argentina
Prior art keywords
level
subject
pharmaceutically acceptable
acceptable salt
compound
Prior art date
Application number
ARP160103143A
Other languages
English (en)
Original Assignee
Advanced Biodesign
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Biodesign filed Critical Advanced Biodesign
Publication of AR106351A1 publication Critical patent/AR106351A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo, en particular el 4-(dimetilamino)-4-metilpent-2-inetioato de S-metilo o una sal farmacéuticamente aceptable del mismo, y más específicamente el S-metil éster fumarato del ácido 4-(dimetilamino)-4-metil-2-pentinetioico, y un compuesto con capacidad para aumentar el nivel de H₂O₂ en las células cancerosas de un sujeto, en particular para usar en el tratamiento del cáncer en un sujeto, donde las células cancerosas de dicho sujeto no sobreproducen H₂O₂ en comparación con un valor control y tienen un nivel de GSH inferior a 5 nmol por 25000 células.
ARP160103143A 2015-10-15 2016-10-14 Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento AR106351A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306650 2015-10-15

Publications (1)

Publication Number Publication Date
AR106351A1 true AR106351A1 (es) 2018-01-03

Family

ID=54360386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103143A AR106351A1 (es) 2015-10-15 2016-10-14 Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento

Country Status (21)

Country Link
US (1) US10406125B2 (es)
EP (1) EP3362094B1 (es)
JP (1) JP7062592B2 (es)
CN (1) CN108348612A (es)
AR (1) AR106351A1 (es)
CA (1) CA3001201C (es)
CY (1) CY1123916T1 (es)
DK (1) DK3362094T3 (es)
ES (1) ES2870508T3 (es)
HK (1) HK1251477A1 (es)
HR (1) HRP20210358T1 (es)
HU (1) HUE054247T2 (es)
IL (1) IL258658B (es)
LT (1) LT3362094T (es)
MX (1) MX2018004381A (es)
PL (1) PL3362094T3 (es)
PT (1) PT3362094T (es)
RS (1) RS61572B1 (es)
SI (1) SI3362094T1 (es)
WO (1) WO2017064241A1 (es)
ZA (1) ZA201802400B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022001620A2 (pt) * 2019-07-31 2022-03-22 Advanced Biodesign Composto, processo para preparar um composto, composição farmacêutica e conjugado anticorpo-droga
FR3119314A1 (fr) * 2021-01-29 2022-08-05 Advanced Biodesign Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable
EP4035666A1 (en) * 2021-01-29 2022-08-03 Advanced Biodesign Aminothiolester compound or derivative thereof for use as an immunomodulatory agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2777001B1 (fr) * 1998-04-01 2000-06-09 Cird Galderma Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses
FR2809727B1 (fr) 2000-05-31 2002-07-26 Galderma Res & Dev Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations

Also Published As

Publication number Publication date
EP3362094A1 (en) 2018-08-22
DK3362094T3 (da) 2021-03-01
WO2017064241A1 (en) 2017-04-20
IL258658A (en) 2018-06-28
SI3362094T1 (sl) 2021-04-30
ES2870508T3 (es) 2021-10-27
LT3362094T (lt) 2021-05-10
IL258658B (en) 2021-04-29
JP2018531995A (ja) 2018-11-01
RS61572B1 (sr) 2021-04-29
CY1123916T1 (el) 2022-05-27
BR112018007480A2 (pt) 2018-10-23
CN108348612A (zh) 2018-07-31
MX2018004381A (es) 2018-05-11
US10406125B2 (en) 2019-09-10
PL3362094T3 (pl) 2021-10-11
HK1251477A1 (zh) 2019-02-01
HRP20210358T1 (hr) 2021-04-16
HUE054247T2 (hu) 2021-08-30
CA3001201A1 (en) 2017-04-20
EP3362094B1 (en) 2021-02-17
PT3362094T (pt) 2021-04-15
ZA201802400B (en) 2020-01-29
JP7062592B2 (ja) 2022-05-06
CA3001201C (en) 2023-07-11
US20180303773A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
MY191574A (en) Pharmaceutical compositions comprising meloxicam
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
MX361590B (es) Suministro topico de composiciones para la piel que tienen ph bajo.
CL2017000866A1 (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
PE20191407A1 (es) Uso de gaboxadol en el tratamiento de tinnitus
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
PE20121700A1 (es) Composicion que comprende l-carnitina o propionil l-carnitina, troxerutina, diosmina y hesperidina
WO2016040169A3 (en) Mucolytic agents for use in tretaing pulmonary sarcoidosis
AR106351A1 (es) Combinación que comprende un compuesto aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto con capacidad para aumentar el nivel del nivel el h₂o₂ en las células cancerosas de un sujeto, para usar como medicamento
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
AR106352A1 (es) Compuestos de aminotioléster o las sales farmacéuticamente aceptables del mismo, para usar en el tratamiento del cáncer
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
MX2017007978A (es) 3-(piperidin-4-il)-isoxazol-3(2h)-onas para tratamiento de trastornos dermatologicos.
ES2721003T3 (es) Utilización de ácido 1, 3 - propano disulfónico o sales farmacéuticamente aceptables del mismo para el tratamiento de la sarcoidosis
CL2018002930A1 (es) (+)-azasetron para uso en el tratamiento de desórdenes de oído.